A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)

Exclusion Criteria

• •Has clinically significant cardiovascular disease within 12 months from first dose of study intervention, including New York Heart Association Class III or IV congestive heart failure, unstable angina, new-onset angina, pulmonary embolism, myocardial infarction, cerebral vascular accident, or cardiac arrhythmia associated with hemodynamic instability
• •Had deep vein thrombosis within 3 months before randomization unless stable, asymptomatic, and treated with therapeutic anticoagulation for at least 4 weeks before randomization
• •Has a left ventricular ejection fraction ≤50% or below the institutional (or local laboratory) normal range as determined by multigated acquisition or echocardiogram
• •Has had major surgery within 8 weeks before randomization or has not adequately recovered from major surgery or has ongoing surgical complications
• •Has current pneumonitis/interstitial lung disease
• •Has symptomatic pleural effusion (for example cough, dyspnea, pleuritic chest pain), ascites, or pericardial fluid requiring drainage within 4 weeks prior to randomization
• •Has a gastrointestinal disorder including those associated with a high risk of perforation or fistula formation
• •Has a serious active nonhealing wound/ulcer/bone fracture
• •Has a requirement for hemodialysis or peritoneal dialysis
• •Has history of human immunodeficiency virus infection
• •Has hepatitis B or hepatitis C virus
• •Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention